张瑞娇,苏 娟

本文对难治性活动性强直性脊柱炎患者伴血小板增多现状、影响因素及其干预进行综述，以国内外相关研究、临床实践及科研工作的开展提供参考，探讨强直性脊柱炎患者的临床特征，分析患者血小板参数及其疾病活动度的关系，为进一步探索强直性脊柱炎治疗提供临床依据。

强直性脊柱炎；脊柱关节炎；原发性血小板增多症；血小板增多

[1] Liao HT,Tsai CY.Cytokines and regulatory T cells in ankylosing spondylitis.Bone Joint Res.2023,12(2):133-137. [2] Dean LE,Jones GT,MacDonald AG,et al.Global prevalence of ankylosing spondylitis.Rheumatology(Oxford).2014,53(4):650-657. [3] 吴珊珊,段振华.强直性脊柱炎流行病学研究进展.安徽医科大学报,2013,48(8):988-992. [4] 中华医学会风湿病学分会,强直性脊柱炎诊断及治疗指南.中华风湿病学杂志.2010,14(8):557-9. [5] Smolen JS,Schöls M,Braun J,et al.Treating axial spondyloarthritis and peripheral spondyloarthritis,especially psoriatic arthritis,to target: 2017 update of recommendations by an international task force.Ann Rheum Dis.2018,77(1):3-17. [6] Braun J,Baraliakos X,Deodhar A,et al.Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the measure study.Rheumatology(Oxford).2019,58(5):859-868. [7] KömürcüE,Akbal E,Coşar M,et al.Neutrophil-Lymphocyte Ratio Connected to Treatment Options and Inflammation Markers of Ankylosing Spondylitis.J Clin Lab Anal.2015,29(4):294-8. [8] Wu J,Yan L,Chai K,et al.Systemic immune-inflammation index is associated with disease activity in patients with ankylosing spondylitis.J Clin Lab Anal.2021,35(9):e23964. [9] Nam B,Koo BS,Lee TH,et al.Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis:a retrospective cohort study.BMC Musculoskelet Disord.2021,22(1):140.Karoli Y,Avasthi S,Mahapatra S,Karoli R.Clinical profile of ankylosing spondylitis at a teaching h [10] Karoli Y,Avasthi S,Mahapatra S,et al.Clinical profile of ankylosing spondylitis at a teaching hospital.Ann Afr Med.2022,21(3):204-207. [11] Koupenova M,Clancy L,Corkrey HA,et al.Circulating Platelets as Mediators of Immunity,Inflammation,and Thrombosis.Circ Res. 2018,122(2):337-351. [12] Lindemann S,Tolley ND,Dixon DA,et al.Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis.J Cell Biol.2001,154(3):485-90. [13] Zufferey A,Fontana P,Reny JL,et al.Platelet proteomics.Mass Spectrom Rev.2012,31(2):331-51. [14] Smith JA.Update on ankylosing spondylitis:current concepts in pathogenesis.Curr Allergy Asthma Rep.2015,15(1):489. [15] Zeremski V,SavićA,IlićT,et al.A case of essential thrombocythemia and ankylosing spondylitis treated with a combination of anagrelide,disease-modifying antirheumatic drugs,and etanercept.Srp Arh Celok Lek.2016,144(1-2):81-4. [15] Deng L,Zheng P.Thrombocytosis in patients with spondyloarthritis:a case-control study.BMC Musculoskelet Disord.2023,15;24(1):195. [16] Koupenova M,Livada AC,Morrell CN.Platelet and Megakaryocyte Roles in Innate and Adaptive Immunity.Circ Res. 2022,21;130(2):288-308. [17] Lv C,Ye D,Zhu Y,et al.Non-genetic biomarkers for ankylosing spondylitis:An umbrella review.J Clin Lab Anal.2022,36(12):e24759.

点击下载PDF